All Oncology News

Dong Kim, MD, discusses the role of NALIRIFOX and other frontline chemotherapy regimens in the pancreatic cancer treatment landscape.

Nivolumab with or without relatlimab exceeded historical benchmarks in TLS-positive soft tissue sarcoma, validating TLS as a predictive biomarker.

Researchers at The University of Texas MD Anderson Cancer Center shared insights about how the immune system can be trained to improve patient outcomes.

OncoMate MSI Dx was approved by the FDA to identify patients with MSS endometrial cancer who may be eligible for pembrolizumab plus lenvatinib.

Findings from the preliminary cohort show 3- and 6-month CR rates of 56% and 62%, respectively, with detalimogene in this patient population.

R. Lor Randall, MD, FACS, advocates for precision-based survivorship models in pediatric/AYA sarcoma to address disparities and improve long-term outcomes.

Incorporating AI into daily workflows may allow oncology professionals to save time on insurance denial claims and re-allocate time back into patient care.

Long-term data reveal deep remissions with eque-cel, suggesting durable disease control with BCMA-directed CAR T-cell therapy in relapsed multiple myeloma.

Erika P. Hamilton, MD, discusses initial efficacy and safety data with the TROP2-targeted ADC DB-1305/BNT325 in pretreated metastatic TNBC.

Daniel J. George, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan in metastatic CRPC and patient selection considerations.

Jose Tinajero, PharmD, BCOP, discusses the role of the pharmacist in treatment planning and management in chronic myeloid leukemia.

The NCCN has released their updated Clinical Practice Guidelines in Oncology for NSCLC.

The phase 3 PEAK trial met its primary PFS end point with bezuclastinib plus sunitinib in imatinib-resistant/intolerant gastrointestinal stromal tumors.

UCSF clinicians present research at SurgeWest 2025, on an RNA biomarker for prostate cancer and opioid prescribing patterns after urologic surgery.

Kevin Kalinsky, MD, MS, FASCO, discusses treatments and targeted therapies in the post–CDK4/6 inhibitor setting of HR+ breast cancer.

Anwar Saeed, MD, discusses findings of zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer.

The top 5 OncLive TV videos of the week cover insights in breast cancer and ovarian cancer.

STK-012 plus pembrolizumab and chemotherapy showed early efficacy and manageable safety in PD-L1–negative NSCLC.

Jennifer Chan, MD, MPH, discusses dose escalation and interval shortening with somatostatin analogs for GEP-NETs and how SORENTO may shape treatment.

The FDA clears subcutaneous daratumumab in smoldering myeloma, adds REMS guidelines for pexidartinib in TGCT, and more.

Use of camizestrant plus a CDK4/6 inhibitor at the emergence of an ESR1 mutation did not significantly worsen visual symptoms in HR-positive breast cancer.

Erica L. Mayer, MD, MPH, discusses data with giredestrant and how the evERA trial shows the potential for SERD-based regimens in ER-positive breast cancer.

Protein METTL7A plays key role in resistance to drugs targeting EGFR-mutant lung adenocarcinoma.

The phase 3 ASCENT-07 trial did not meet its primary PFS end point with first-line sacituzumab govitecan in hormone receptor–positive, HER2-negative breast cancer.

The FDA has approved generic dasatinib tablets for select patients with chronic myeloid leukemia and acute lymphoblastic leukemia.

Marlana Orloff, MD, discusses data for the combination of darovasertib and crizotinib in metastatic uveal melanoma.

Surbhi Sidana, MD, and Joshua Richter, MD, discuss the FDA approval of BVd for relapsed/refractory myeloma after at least 2 prior lines of therapy.

The FDA has approved daratumumab and hyaluronidase-fihj for the treatment of adult patients with high-risk smoldering multiple myeloma.

GFH375 produced responses and tumor shrinkage in heavily pretreated pancreatic ductal adenocarcinoma harboring KRAS G12D mutations.

Researchers conducted the largest, most comprehensive molecular analysis of RMC, leading to the identification of TROP2 as a promising therapeutic target.